Quiver Bioscience Inc. has received a strategic investment from the Porta family office (Argentina) to advance the company’s antisense oligonucleotide (ASO) therapeutic program for chromosome 15q duplication (Dup15q) syndrome. The investment will fund preclinical activities, including safety studies for candidate selection as the program advances toward clinical development.

Vivatides Therapeutics Inc. has closed an oversubscribed $54 million series A financing to advance its work in extrahepatic RNA delivery technologies. Proceeds from the financing will be used to further advance the company’s extrahepatic delivery platform and accelerate pipeline programs.

Founded amid the booming next-generation antibody-drug conjugate (ADC) space, Sidewinder Therapeutics Inc. has emerged from stealth with an oversubscribed $137 million series B round and plans to advance a lead program into the clinic in 2027.

Stipple Bio Inc. raised $100 million in a series A financing to support progression of the company’s lead drug, STP-100, an antibody-drug conjugate that binds an undisclosed target, and the company’s Pointillist discovery platform. The round was co-led by RA Capital, a16z Bio+Health and Nextech Invest. Existing investors, including Emerson Collective Investments (managed by Yosemite), GV (Google Ventures), Lola Capital Partners, GordonMD Global Investments and others, also participated in the round.

Tippingpoint Biosciences Inc. has closed an oversubscribed $4.5 million seed financing. The company, spun out of a lab at University of California, San Francisco (UCSF), is advancing its novel drug discovery platform designed to identify first-in-class drugs to treat diseases related to dysfunctional DNA packaging (chromatin).

Ambrosia Biosciences Inc. has announced a $100 million oversubscribed series B financing intended to support progression of the company’s oral small-molecule GLP-1 candidate and other novel cardiometabolic programs into clinical development.

Marvel Biosciences Corp., together with its wholly owned subsidiary Marvel Biotechnology Inc., has announced nondilutive funding from the Alberta Innovates CarE (AICE) market access program to support progression into the clinic and phase I testing of lead compound, MB-204. MB-204, a fluorinated derivative version of istradefylline, offers potential as a new approach totreating autism spectrum disorders and related conditions, addressing socio-behavioral symptoms through a differentiated mechanism.

Pinnacle Medicines Inc. secured $89 million in a series B financing, bringing the total raised by the company to $134 million. The round was co-led by LAV and Foresite Capital.

Rybodyn Inc. has announced the initial close of a $10 million seed financing to support its work decoding the dark proteome using an AI-powered novel sequencing and discovery platform. The financing will accelerate the company’s transition from foundational discovery into scaled platform execution and progress early-stage programs into IND-enabling studies.

Epifrontier Therapeutics Inc. has been awarded a grant of up to $32 million in nondilutive funding from the Japan Agency for Medical Research and Development (AMED) to advance the clinical development of EPF-001 (RK-701), a first-in-class G9a inhibitor being developed for sickle cell disease and β-thalassemia.